Arcutis
Arcutis Gets FDA Nod for Topical Foam
Westlake Village-based immunodermatology company Arcutis Biotherapeutics Inc. has received approval from the Food and Drug Administration for a topical foam version of its main drug to treat seborrheic dermatitis in individuals aged 9 and older. The approval, announced last month, marks the first new method of application for a drug to treat seborrheic dermatitis in […]
Arcutis Gets FDA Nod For Dermatitis Cream
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval to begin marketing its drug to treat a type of dermatitis in children ages 6 to 11. The company had already received approval to market the drug for use in people 12 and over. Separately, the company this month announced a public offering of $100 million […]
Arcutis Gets FDA Nod For Plaque Psoriasis Cream
This article has been revised and corrected from the original version. Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval to begin marketing its drug to treat plaque psoriasis in children ages 6 to 11. The company had already received approval to market the drug for use in people 12 and over. Separately, the […]